EUVIMEDEUVIMED entdecken
Crossref

Antiviral therapy reduces hepatocellular carcinoma through suppressing hepatitis B virus replication may improve ER stress, mitochondrial and metabolic dysfunctions and decrease p62 in hybridized mice with single HBV transgene and miR‐122

Yuh-Jin Liang iD, Yu-Wei Chiou, Abby Pei-Ting Chiu, Ming-Shi Shiao, Wei Teng, Chin-Wei Lin, Mei-Ling Cheng, Yen-Hua Huang, Kung-Hao Liang, Chien-Wei Su, Chi-Yu Lai, Chih-Li Chen und 1 weitere

Journal of Medical Virology · 2023

DOI: 10.1002/jmv.29325 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Yuh-Jin Liang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research Division, Medical Research Department, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis B, Chronic, MicroRNAs. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Yang Ming Chiao Tung University, Ministry of Health and Welfare, Taipei Veterans General Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatitis B virus (HBV) hijacks autophagy for its replication. Nucleos(t)ide analogs (NUCs) treatment suppressed HBV replication and reduced hepatocellular carcinoma (HCC) incidence. However, the use of NUCs in chronic hepatitis B (CHB) patients with normal or minimally elevated serum alanine aminotransferase (ALT) levels is still debated. Animal models are crucial for studying the unanswered issue and evaluating new therapies. MicroRNA‐122 (miR‐122), which regulates fatty acid and cholesterol metabolism, is downregulated during hepatitis and HCC progression. The reciprocal inhibition of miR‐122 with HBV highlights its role in HCC development as a tumor suppressor. By crossbreeding HBV‐transgenic mice with miR‐122 knockout mice, we generated a hybrid mouse model with a high incidence of HCC up to 89% and normal ALT levels before HCC. The model exhibited early‐onset hepatic steatosis, progressive liver fibrosis, and impaired late‐phase autophagy. Metabolomics and microarray analysis identified metabolic signatures, including dysregulation of lipid metabolism, inflammation, genomic instability, the Warburg effect, reduced TCA cycle flux, energy deficiency, and impaired free radical scavenging. Antiviral treatment reduced HCC incidence in hybrid mice by approximately 30–35% compared to untreated mice. This effect was linked to the activation of ER stress‐responsive transcription factor ATF4, clearance of autophagosome cargo p62, and suppression of the CHOP‐mediated apoptosis pathway. In summary, this study suggests that despite minimal ALT elevation, HBV replication can lead to liver injury. Endoplasmic reticulum stress, reduced miR‐122 levels, mitochondrial and metabolic dysfunctions, blocking protective autophagy resulting in p62 accumulation, apoptosis, fibrosis, and HCC. Antiviral may improve the above‐mentioned pathogenesis through HBV suppression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHepatitis B, ChronicMicroRNAsHumansMiceAnimalsHepatitis B virusMice, TransgenicVirus ReplicationAntiviral Agents

Stichwörter der Autor:innen

autophagyendoplasmic reticulum stressmetabolic dysregulationmiR-122mitochondrial dysfunction

Substanzen

MicroRNAsAntiviral AgentsMIRN122 microRNA, humanMirn122 microRNA, mouse

Autor:innen und Institutionen

  • Translational Research Division, Medical Research Department, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
  • Cancer Progression Research Center, National Yang Ming Chiao Tung University, Taiwan, ROC.
  • Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
  • Department of Anesthesiology & Pain Medicine, University of Washington, Seattle, Washington, USA.
  • Department of Biology, University of Washington, Seattle, Washington, USA.
  • Metabolomics Core Laboratory, Healthy Aging Research Center, Chang Gung University, Taoyuan, Taiwan, ROC.

ORCID-Profile: Yuh-Jin Liang

Förderung

  • National Yang Ming Chiao Tung University
  • Ministry of Health and Welfare
  • Taipei Veterans General Hospital
  • National Science and Technology Council
  • Ministry of Education (MOE) of Taiwan

Zitieren

APA

Liang, Y. J., Chiou, Y. W., Chiu, A. P., Shiao, M. S., Teng, W., Lin, C. W., Cheng, M. L., Huang, Y. H., Liang, K. H., Su, C. W., Lai, C. Y., Chen, C. L., & Wu, J. C. (2023). Antiviral therapy reduces hepatocellular carcinoma through suppressing hepatitis B virus replication may improve ER stress, mitochondrial and metabolic dysfunctions and decrease p62 in hybridized mice with single HBV transgene and miR‐122. Journal of Medical Virology. https://doi.org/10.1002/jmv.29325

Vancouver

Liang YJ, Chiou YW, Chiu AP, Shiao MS, Teng W, Lin CW, et al. Antiviral therapy reduces hepatocellular carcinoma through suppressing hepatitis B virus replication may improve ER stress, mitochondrial and metabolic dysfunctions and decrease p62 in hybridized mice with single HBV transgene and miR‐122. Journal of Medical Virology. 2023. doi:10.1002/jmv.29325

BibTeX
@article{Liang2023,
  author = {Liang, Yuh-Jin and Chiou, Yu-Wei and Chiu, Abby Pei-Ting and Shiao, Ming-Shi and Teng, Wei and Lin, Chin-Wei and Cheng, Mei-Ling and Huang, Yen-Hua and Liang, Kung-Hao and Su, Chien-Wei and Lai, Chi-Yu and Chen, Chih-Li and Wu, Jaw-Ching},
  title = {Antiviral therapy reduces hepatocellular carcinoma through suppressing hepatitis B virus replication may improve ER stress, mitochondrial and metabolic dysfunctions and decrease p62 in hybridized mice with single HBV transgene and miR‐122},
  journal = {Journal of Medical Virology},
  year = {2023},
  doi = {10.1002/jmv.29325}
}
Kostenlos starten →